Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Boris Schmidt Added: 1 year ago
EHRA 24 - Investigator, Dr Boris Schmidt (Cardioangiologisches Centrum Bethanien, DE) is interviewed on ablation strategies for repeat procedures in patients with recurrent atrial fibrillation (AF).The ASTRO trial is a multi-centre prospective randomized study that enrolled 256 patients with drug-refractory AF despite previous AF ablation. The trial showed no statistically significant differences… View more
Author(s): Chao Jiang , Zhao Zixu Added: 2 months ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more
Author(s): Atul Verma Added: 6 days ago
Dr Atul Verma (McGill University Health Centre & McGill University, Montreal, CA, US) joins us to discuss findings from the VOLT AF IDE trial, evaluating a novel balloon-in-basket pulsed field ablation system that integrates mapping and ablation capabilities.The prospective, multicenter VOLT AF IDE study evaluated safety and effectiveness of the Volt™ PFA system in patients with symptomatic,… View more
Author(s): Vivek Reddy Added: 4 days ago
AF Symposium 2026 - Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss findings from the ADVENT LTO study, evaluating long-term outcomes and atrial fibrillation progression in patients who received ablation with the FARAPULSE Pulsed Field Ablation System compared to thermal ablation.The study tracked AF progression patterns, arrhythmia recurrence rates,… View more
Author(s): Vivek Reddy Added: 1 week ago
Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss evolving strategies for stroke management following atrial fibrillation ablation, addressing the critical question of when anticoagulation can be safely discontinued after successful ablation.Interview Questions:There's been a lot of talk about optimal anticoagulation – what's the headline? In which… View more
Author(s): Gregory Piazza Added: 5 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more
Author(s): Vivek Reddy Added: 3 months ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then… View more
Author(s): Nazli Okumus , Jeffrey L Carson Added: 2 years ago
AHA 2023 — Investigator, Dr Jeffrey Carson (Rutgers University, US) joined Dr Nazli Okumus, CardioNerds Ambassador to discuss findings from the MINT trial (NCT02981407).The aim of this randomised, parallel assignment trial (Rutgers) is to compare liberal and restrictive red blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anemic… View more
Author(s): Tina Baykaner , Boris Schmidt , Atul Verma , et al Added: 5 days ago
Stay up to date with our video collection covering late-breaking data from AF Symposium 2026 in Boston. Don't miss our short, accessibleExpert Interviews, Discussions and Highlights of the most pertinent trials. View more